8-K: Pasithea Therapeutics Appoints New Chief Medical Officer

Pasithea Therapeutics Corp. announced the appointment of Dr. Kartik Krishnan as Chief Medical Officer, effective May 1, 2026, to lead clinical development for PAS-004.

Summary

• Pasithea Therapeutics Corp. has appointed Dr. Kartik Krishnan as its new Chief Medical Officer (CMO), effective May 1, 2026.
• Dr. Krishnan will be responsible for overseeing all clinical development and medical strategy, particularly for the advancement of PAS-004, a drug candidate for neurofibromatosis type 1 (NF1).
• Dr. Krishnan brings over 20 years of experience in clinical development and has previously held leadership roles at companies like OncoNano Medicines and Arcus Biosciences.
• He was also a key member of the clinical team for cobimetinib (Cotellic) at Genentech, which was approved for melanoma.
• In connection with his appointment, Dr. Krishnan will receive an annual base salary of $500,000 and is eligible for an annual bonus of up to 40% of his base salary.
• The company also approved stock option awards for executive officers, employees, and non-employee directors, with an exercise price of $0.841 per share as of May 1, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the strategic appointment of an experienced CMO and the alignment of incentives through stock options, which are crucial for advancing clinical programs.

Positives

• Appointment of a highly experienced Chief Medical Officer with over 20 years in clinical development and a track record of advancing therapies.
• Dr. Krishnan's experience with MEK inhibitors, specifically cobimetinib, is directly relevant to Pasithea's PAS-004 program.
• The company has granted stock options to key personnel, aligning incentives and reflecting recent capital raises.
• Dr. Krishnan's compensation package includes a base salary of $500,000 and potential bonus, indicating a competitive offer.
• The company is advancing PAS-004 for the treatment of NF1-associated plexiform and cutaneous neurofibromas.

Negatives

• The filing does not contain any negative financial results or operational setbacks.
• The employment agreement is at-will, meaning either party can terminate the relationship.
• Severance benefits are contingent upon the execution of a separation agreement and release of claims.

Risks

• The success of PAS-004 is subject to clinical trial outcomes, which may not meet expectations or regulatory requirements.
• The company's stock options are subject to vesting schedules and continued service.
• Dr. Krishnan's employment is at-will and can be terminated by either party.
• Potential for future clawbacks of compensation as per the company's clawback policy.

Future Outlook

The company is advancing PAS-004 through clinical trials for neurofibromatosis type 1, with the new CMO expected to lead clinical development and medical strategy.

Management Comments

• "We are delighted to welcome Dr. Krishnan, who is recognized for his strategic approach to clinical development and commitment to improving patient outcomes, to our executive leadership team."
• "We believe his experience developing cobimetinib, a FDA-approved MEK inhibitor, is particularly relevant to our mission, and that his expertise will directly benefit the progression of our PAS-004 program."
• "I am honored to join Pasithea at this point in the Company's evolution, and excited for the opportunity to lead the development of PAS-004 in NF1 and potentially for other rare and pediatric diseases."
• "PAS-004 has demonstrated a differentiated pharmacokinetic (PK) profile that may hit the sweet spot between safety, tolerability and efficacy."

Industry Context

StockSavvy.ai notes that the appointment of a seasoned Chief Medical Officer with specific experience in MEK inhibitors is a positive development for a clinical-stage biotechnology company like Pasithea Therapeutics, especially as it advances its lead candidate, PAS-004, in a targeted indication.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced CMO and the granting of stock options are intended to drive value and align management with shareholder interests.
• Employees: The stock option grants extend to employees, providing an incentive for performance and retention.
• Management: The new CMO receives a competitive compensation package, including salary and equity.
• Directors: Non-employee directors also received stock option awards.

Next Steps

• Dr. Krishnan will oversee clinical development and medical strategy for PAS-004.
• The company will continue to advance PAS-004 through clinical trials for NF1.
• Stock options granted will vest over time, subject to continued service.

Key Dates

Recommendation

The filing announces a key executive appointment and associated compensation, which is a standard operational update. While positive, it does not provide new clinical data or significant financial performance indicators that would warrant a strong buy or sell recommendation at this juncture. A 'hold' recommendation reflects the ongoing development stage and the need for further clinical and financial updates.

Keywords

Pasithea Therapeutics, Chief Medical Officer, Kartik Krishnan, PAS-004, Neurofibromatosis Type 1, Clinical Development, Biotechnology, Stock Options